Literature DB >> 18850761

The impact of influenza on working days lost: a review of the literature.

Martin Keech1, Paul Beardsworth.   

Abstract

Seasonal influenza is a prevalent and highly contagious acute respiratory disease that, year on year, results in increased morbidity and mortality on a global scale. Because of the widespread and debilitating nature of the disease, annual influenza epidemics result in substantial workplace absenteeism, and the associated cost of lost productivity is a significant component of the substantial financial burden of the disease to society. The objective of this review was to identify studies that had attempted to quantify the impact of influenza upon otherwise healthy adults in terms of working days lost associated with an episode of influenza.Studies were included if they reported estimates of working days lost due to clinical, physician and/or self-diagnosis in adult patients or their dependants, or where this figure could be estimated from the data. Searches were conducted in MEDLINE, EMBASE, BIOSIS and the Cochrane Collaboration for articles published since 1995 in English, French or German. Of the 289 papers identified in the search, 28 (9.7%) met the inclusion criteria. The studies, involving study sites in North America, Western Europe, Asia and Australia, were categorized into three groups: (i) those reporting influenza diagnoses confirmed by laboratory testing, i.e. studies where influenza was the unambiguous cause of the working days lost (n = 7 studies reported in ten publications); (ii) those where influenza was confirmed by a physician without an accompanying laboratory test (n = 4 studies); and (iii) those where influenza was self-reported by study participants (n = 14 studies). Qualitative reporting of results was performed because of the large degree of heterogeneity observed between studies, potentially complicating the interpretation of any meta-analysis.The results from studies involving a laboratory-confirmed influenza diagnosis suggested that the mean number of working days lost ranged between 1.5 and 4.9 days per episode. Those papers that detailed working days lost per episode following physician diagnosis of influenza reported a range of 3.7-5.9 days per episode. Finally, estimates from papers reporting working days lost per episode of self-reported influenza ranged from <1 day to 4.3 days per episode.Influenza imposes a significant burden on society, and this review highlights the significant economic impact it causes, i.e. the loss of productivity caused by both absenteeism and by staff functioning at reduced capacity even after they have returned to work. A number of prophylaxis and treatment options exist for influenza and should be given serious consideration in an attempt to reduce the economic burden on society.

Entities:  

Mesh:

Year:  2008        PMID: 18850761     DOI: 10.2165/00019053-200826110-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  73 in total

Review 1.  Amantadine and rimantadine for influenza A in adults.

Authors:  T Jefferson; V Demicheli; C Di Pietrantonj; D Rivetti
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.

Authors:  Roben Das Gupta; Julian F Guest
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Impact of influenza vaccination on civilian aircrew illness and absenteeism.

Authors:  Marias A G Mixéu; Glaucia N R Vespa; Eduardo Forleo-Neto; João Toniolo-Neto; Paulo M Alves
Journal:  Aviat Space Environ Med       Date:  2002-09

4.  Economic and social impact of epidemic and pandemic influenza.

Authors: 
Journal:  Vaccine       Date:  2006-11-10       Impact factor: 3.641

5.  The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population.

Authors:  M Keech; A J Scott; P J Ryan
Journal:  Occup Med (Lond)       Date:  1998-02       Impact factor: 1.611

6.  Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.

Authors:  A S Monto; D M Fleming; D Henry; R de Groot; M Makela; T Klein; M Elliott; O N Keene; C Y Man
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

7.  The incidence, natural history and associated outcomes of influenza-like illness and clinical influenza in Italy.

Authors:  A Sessa; B Costa; F Bamfi; G Bettoncelli; G D'Ambrosio
Journal:  Fam Pract       Date:  2001-12       Impact factor: 2.267

8.  Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine.

Authors:  Kristin L Nichol; Kenneth P Mallon; Paul M Mendelman
Journal:  Vaccine       Date:  2003-05-16       Impact factor: 3.641

9.  Current estimates from the National Health Interview Survey, 1995.

Authors:  V Benson; M A Marano
Journal:  Vital Health Stat 10       Date:  1998-10

10.  Impact of human metapneumovirus in childhood: comparison with respiratory syncytial virus and influenza viruses.

Authors:  Samantha Bosis; Susanna Esposito; Hubert G M Niesters; Piero Crovari; Albert D M E Osterhaus; Nicola Principi
Journal:  J Med Virol       Date:  2005-01       Impact factor: 2.327

View more
  72 in total

1.  Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013.

Authors:  Joshua G Petrie; Caroline Cheng; Ryan E Malosh; Jeffrey J VanWormer; Brendan Flannery; Richard K Zimmerman; Manjusha Gaglani; Michael L Jackson; Jennifer P King; Mary Patricia Nowalk; Joyce Benoit; Anne Robertson; Swathi N Thaker; Arnold S Monto; Suzanne E Ohmit
Journal:  Clin Infect Dis       Date:  2015-11-12       Impact factor: 9.079

2.  Influenza-like illness in a community surrounding a school-based outbreak of 2009 pandemic influenza A (H1N1) virus-Chicago, Illinois, 2009.

Authors:  Kristen B Janusz; Jennifer E Cortes; Fadila Serdarevic; Roderick C Jones; Joshua D Jones; Kathleen A Ritger; Julie Y Morita; Susan I Gerber; L Gallagher; Brad J Biggerstaff; Lauri A Hicks; David L Swerdlow; Marc Fischer; J Erin Staples
Journal:  Clin Infect Dis       Date:  2011-01-01       Impact factor: 9.079

3.  Influenza vaccination of parents and guardians by US pediatricians.

Authors:  Seth L Toback; William Carr; Jesse Hackell; Praful Bhatt; Amy Ryan; Christopher S Ambrose
Journal:  Hum Vaccin       Date:  2011-04-01

4.  The healthy workplace project: Reduced viral exposure in an office setting.

Authors:  Kelly A Reynolds; Paloma I Beamer; Kevin R Plotkin; Laura Y Sifuentes; David W Koenig; Charles P Gerba
Journal:  Arch Environ Occup Health       Date:  2015-06-11       Impact factor: 1.663

5.  Employer-incurred health care costs and productivity losses associated with influenza.

Authors:  Sudeep Karve; Derek A Misurski; Genevieve Meier; Keith L Davis
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

6.  To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling.

Authors:  Bruce Y Lee; Sarah M McGlone; Rachel R Bailey; Ann E Wiringa; Shanta M Zimmer; Kenneth J Smith; Richard K Zimmerman
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

7.  Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method.

Authors:  Mario M Alvarez; Felipe López-Pacheco; José M Aguilar-Yañez; Roberto Portillo-Lara; Gonzalo I Mendoza-Ochoa; Sergio García-Echauri; Pamela Freiden; Stacey Schultz-Cherry; Manuel I Zertuche-Guerra; David Bulnes-Abundis; Johari Salgado-Gallegos; Leticia Elizondo-Montemayor; Martín Hernández-Torre
Journal:  PLoS One       Date:  2010-04-14       Impact factor: 3.240

8.  Workplace vaccination and other factors impacting influenza vaccination decision among employees in Israel.

Authors:  Shosh Shahrabani; Uri Benzion
Journal:  Int J Environ Res Public Health       Date:  2010-03-08       Impact factor: 3.390

9.  Tempo and mode in the molecular evolution of influenza C.

Authors:  Derek Gatherer
Journal:  PLoS Curr       Date:  2010-11-30

Review 10.  Intanza (®) 9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age.

Authors:  Isabel Leroux-Roels; Françoise Weber
Journal:  Hum Vaccin Immunother       Date:  2013-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.